Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational topical formulation consists of cannabidiol (CBD) oil applied in conjunction with a silicone patch. Developed by the University of Oklahoma Health Sciences Center, it is specifically designed to improve scar healing and appearance in adult patients following paramedian forehead flap (PMFF) reconstruction surgery. The active ingredient, cannabidiol, is a non-psychotropic cannabinoid that targets the cannabinoid receptor 2 (CB2). By activating CB2 receptors, the drug aims to reduce inflammation and excessive scar formation while simultaneously promoting skin cell proliferation and wound closure. The product is currently being evaluated in Phase 1 split-scar randomized controlled trials (the TOPSCAR study), where it is compared directly against a standard-of-care silicone patch alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabidiol + silicone patch.